NCT01314092
Terminated
Phase 2
Phase II Study to Evaluate Efficacy and Safety of ANTG-ASC (Autologous Cultured Adipose-derived Stem Cells) on the Complex Fistula Patients
Anterogen Co., Ltd.6 sites in 1 country15 target enrollmentJanuary 2011
ConditionsComplex Perianal Fistula
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Complex Perianal Fistula
- Sponsor
- Anterogen Co., Ltd.
- Enrollment
- 15
- Locations
- 6
- Primary Endpoint
- Number of patients with complete closure of fistula (week 8)
- Status
- Terminated
- Last Updated
- 9 years ago
Overview
Brief Summary
Mesenchymal stem cells derived from adipose tissue are pluripotent to differentiate into myocytes, adipocytes or others. They have an immunosuppressive activity. Complex perianal fistula is difficult to cure and easy to relapse. Autologous adipose stem cells have shown efficacy and safety on Crohn's fistula in phase 1 study. Based on these results, the investigators would apply autologous adipose stem cells on complex perianal fistula to evaluate their efficacy and safety.
Investigators
Eligibility Criteria
Inclusion Criteria
- •a patient who has complex perianal fistula
- •a patient who is negative in pregnancy test
- •a patient who has submitted a written consent
Exclusion Criteria
- •a patient who has participated in other clinical studies within 30 days before this clinical trial or has not passed 5 fold period of a half-life of other investigational drugs.
- •a patient who has a history of variant Creutzfeldt Jacobs disease or related diseases
- •a patient who is allergic to anesthetics, bovine derived proteins or a fibrin glue
- •a patient who has an autoimmune disease
- •a patient who has infectious diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV)
- •a patient who has sepsis or active tuberculosis
- •a patient who is pregnant or breast feeding
- •a patient who has inflammatory Bowel disease
- •over 2cm in diameter of fistula
Outcomes
Primary Outcomes
Number of patients with complete closure of fistula (week 8)
Time Frame: 8 weeks
Proportion of patients with completely closed fistula (week 8)
Secondary Outcomes
- Grade of investigator's satisfaction(8 weeks)
- Number of patients with closed fistula(8 weeks)
- Photo of target fistula(8 weeks)
- Number of patients with adverse events(8 weeks)
Study Sites (6)
Loading locations...
Similar Trials
Completed
Phase 1
Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic PatientsCritical Limb Ischemia (CLI)DiabetesNCT01257776Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud33
Unknown
Not Applicable
Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart FailureIschemic Heart FailureNCT01709279Kanazawa University6
Completed
Phase 1
Adipose Stem Cells for Traumatic Spinal Cord InjurySpinal Cord InjuriesParalysisNCT03308565Mohamad Bydon10
Unknown
Phase 2
Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host DiseaseChronic Graft Versus Host DiseaseNCT01526850Chinese Academy of Medical Sciences100
Completed
Phase 1
Treatment CLI Nonrevascularizable Lower Limb With Cell TherapyNonrevascularizable Critical Ischemia of the Lower LimbsNCT01824069Instituto de Investigación Hospital Universitario La Paz10